Global Gabapentin Market Assessment, By Dosage Form [Oral Solution, Tablet, Capsule], By Application [Restless Legs Syndrome, Neuropathic Pain, Epilepsy, Others], By Route of Administration [Intravenous, Oral, Parenteral], By Mode of Purchase, [Over the Counter, Prescription, Retail], By Distribution Channel [Retail Pharmacy, Hospital Pharmacy, Online Pharmacy, Others], By Region, Opportunities and Forecast, 2017-2031F
Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.
Home>Industry Reports>Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F
Global gabapentin market is projected to witness a CAGR of 5.2% during the forecast period 2024-2031, growing from USD 2.51 billion in 2023 to USD 3.77 billion in 2031F. The market demand is boosted by increasing investments in product innovation activities by pharmaceutical companies, growing provision of product approvals by different regulatory bodies, and rising incidences of seizures.
Pharma companies are actively investing in research and development. For instance, in 2023, Swiss healthcare companies Novartis and Roche ramped up their research and development spending by 6%, with Novartis investing approximately USD 12.1 billion in investments in neuroscience and oncology and Roche investing USD 12.1 billion. Merck & Co. were noted to have the highest R&D ratio of 51%, followed by Novartis and Roche, at 30% each. Such investments aid in the development of novel products and in determining the alternate uses of existing products, which in turn is accelerating the gabapentin market growth.
The expansion of the geriatric population is another major factor bolstering the global gabapentin market demand as they are more susceptible to various health conditions, such as restless legs syndrome, neuropathic pain, epilepsy, and others, that require gabapentin. Thus, due to the growing prevalence of these conditions in the geriatric population, the demand for gabapentin is increasing, thereby bolstering the market's revenue growth.
Additionally, the increasing deployment of gabapentin by the healthcare sector is attributed to the increasing cases of epilepsy in various regions across the globe. For instance, according to the World Health Organization (WHO), epilepsy is one of the most common neurological conditions, with approximately 50 million individuals suffering from it across the globe. The different possible causes of epilepsy include strokes, tumors, imbalance of neurotransmitters, nerve-signaling chemicals, and brain damage caused by injury. Thus, due to these factors, the number of cases of epilepsy is significantly rising, propelling the requirement for gabapentin for effective management of the condition, thereby providing lucrative growth opportunities to the market.
Moreover, the Global Medicine Spending and Usage Trends: Outlook to 2025 report suggests that the medicines market is expected to grow at a CAGR of 3-6% by 2025, reaching approximately USD 1.6 trillion. Thus, the pharmaceutical market will offer lucrative growth opportunities to the global gabapentin market over the coming years.
Prevalence of Neuropathic Pain is Accelerating Market Expansion
The increasing prevalence of neuropathic pain due to damage to nerves, alcoholism, multiple sclerosis, spine injury, diabetes, thyroid disease, and others is one of the major factors boosting the global gabapentin market size. For instance, in 2021, the IDF Diabetes Atlas reported that 10.5% of the individuals from age group 20-79 years are living with diabetes. They project that by 2045, one out of eight adults (about 783 million) will suffer from diabetes. Hence, the increase in the cases of diabetes is propelling the requirement for gabapentin as over long durations of time; uncontrolled high blood sugar might cause damage to nerves, interfering with their ability to send signals, and causing diabetic neuropathy.
Meanwhile, the expansion of the geriatric population is bolstering the product requirement. For instance, according to an article published on PAIN Reports in March 2023, estimates of neuropathic pain in the general population indicate a prevalence of 7-10%. The number increases to approximately 20-30% in individuals with diabetes. Earlier studies have indicated a higher prevenance of neuropathic pain in older populations. Hence, due to it the demand for gabapentin is increasing for effective management of neuropathic pain in this population, which is propelling the expansion of the market.
Government Initiatives to Boost Awareness of Non-Communicable Chronic Conditions Aids Global Gabapentin Market Growth
The growing initiatives by various governments across the globe to increase awareness about epilepsy, among other non-communicable chronic conditions and the available treatments, are augmenting the market expansion. For instance, according to the estimates of the World Health Organization (WHO), approximately five million individuals around the world are diagnosed with epilepsy every year, propelling the requirement for medication to treat epilepsy, including gabapentin. To support this condition, the 75th WHA adopted the Intersectoral global action plan on epilepsy and other neurological disorders 2022–2031. They recognize the shared psychosocial and pharmacological approaches between epilepsy and other neurological disorders, serving as entry points to strengthen the support provided for these conditions. Therefore, due to the implementation of such initiatives, the awareness about epilepsy and the available treatment solutions is increasing; this, in turn, is propelling the requirement for gabapentin and positively influencing the growth of the market.
North America is Anticipated to Account for a Significant Market Share
The presence of a well-established healthcare sector, easy availability and adoption of technologically advanced solutions, and accessibility to health insurance are some of the major factors supporting the growth of North America gabapentin market. The surging provision of approvals by different regulatory bodies, such as the United States Food and Drug Administration (USFDA), coupled with increasing initiatives by pharmaceutical companies and governments to enhance awareness about neurological conditions and their treatments, further support the market growth.
For instance, in March 2024, Strides Pharma Science Limited received approval by the USFDA for gabapentin tablets USP in 800mg and 600mg. The approval is expected to enhance Stride’s product portfolio and help it cater to the requirements of individuals suffering from neurological conditions. The approval complements the company’s existing approvals that hold a market size of USD 208 million.
Additionally, various pharma players and product manufacturers headquartered in the region are heavily investing in research and development activities to support the development of novel medications, further providing lucrative growth opportunities to the market in North America.
For instance, in 2023 Pfizer generated revenue of approximately USD 58 billion and invested around USD 10 billion in research and development, capping the R&D ratio at 18%. Henceforth, such increased investments are expected to support innovations and different methodological processes that aim to develop and introduce various medications into the market, bolstering the global gabapentin market expansion.
Increasing Incidences of Epilepsy Boosts the Market Growth
Epilepsy is a disorder of the brain that is caused by brain tumors, infection in the central nervous system, stroke, and traumatic brain injury. The oral dosage of gabapentin for epilepsy, for adults includes three doses a day of 300 mg, depending upon the recommendation of the physician. However, the dose should not exceed more than 1800 mg per day. For children aged 3-11, the dose is determined by the doctor depending upon the body weight and is initially approximately 10-15 mg per kilogram and is adjusted into three doses per day.
For instance, according to the estimates of the Centers for Disease Control and Prevention, approximately 1.2% of the population of the United States suffer from active epilepsy. The condition affects approximately 470,000 children and 3 million adults in the country. It, in turn is augments the requirement for gabapentin for preventing seizures by supporting the reduction of abnormal electrical activity in brain. Thus, the rising awareness about the condition and increased acceptance of different therapeutic solutions including gabapentin is expected to offer lucrative growth opportunities to the market.
Hospital Pharmacies are Expected to Account for Significant Global Gabapentin Market Share
The segment expansion can be attributed to increasing integration of electronic prescription systems by hospital pharmacies. These systems enhance patient satisfaction and compliance by aiding in streamlining the practice workflow and reducing the number of callbacks from pharmacies to physicians, boosting customer convenience. Due to these benefits the segment is witnessing rapid growth.
For instance, Apollo Hospital's pharmacy business is expected to touch USD 1.2 billion (INR 10,000 crore) revenue by the end of 2024. The rise can be attributed to the consumer preference for purchasing medication for managing chronic health conditions such as epilepsy from reputed hospital pharmacies because of pre-established trust and the presence of helpful pharmacists. Henceforth, such expansions will ensure accessibility to anti-epileptic medications, including gabapentin, supporting the market's growth.
Future Market Scenario (2024 – 2031F)
· According to the global gabapentin market analysis, the increase in cases of restless leg syndrome, neuropathic pain, and epilepsy over the coming years will augment the requirement for gabapentin for treating and managing these conditions, thereby bolstering the market expansion.
· The rising conduction of clinical trials for determining the doses of antiepileptic drugs, including gabapentin required for treating different epileptic conditions and augmenting investments towards research and development activities for identifying the alternative applications of gabapentin are expected to offer lucrative growth opportunities to the market over the forecast period.
· The ongoing development of new healthcare facilities will boost the supply of gabapentin across various regions, thereby creating a favorable growth potential for the growth of the market in the long run.
Report Scope
“Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gabapentin market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2023 |
|
Historical Period |
2017-2022 |
|
Forecast Period |
2024-2031F |
|
Projected Growth Rate |
CAGR of 5.2% between 2024-2031F |
|
Revenue Forecast in 2031 |
USD 3.77 billion |
|
Segments Covered |
Dosage Form, Application, Route of Administration, Mode of Purchase, Distribution Channel |
|
Regions Covered |
North America, Europe, South America, Asia-Pacific, Middle East and Africa |
|
Key Companies Profiled |
Pfizer Inc., Zydus Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd., Cipla USA, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Ascend Laboratories, LLC, Amneal Pharmaceuticals, Inc., Apotex Inc. |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In the report, global gabapentin market has been segmented into the following categories:
· By Dosage Form
o Oral Solution
o Tablet
o Capsule
· By Application
o Restless Legs Syndrome
o Neuropathic Pain
o Epilepsy
o Others
· By Route of Administration
o Intravenous
o Oral
o Parenteral
· By Mode of Purchase
o Over-the-Counter
o Prescription
o Retail
· By Distribution Channel
o Retail Pharmacy
o Hospital Pharmacy
o Online Pharmacy
o Others
· By Region
o North America
o South America
o Europe
o Asia-Pacific
o Middle East & Africa
Key Players Landscape and Outlook
Various leading market players are investing heavily in research and development activities to strengthen their position in the market. These activities allow them to develop new products, evaluate the working and functioning of existing products for different applications, and assess the safety and efficacy of both existing and novel products. This allows the company to send more products for approval to different regulatory bodies such as the United States Food and Drug Administration (USFDA).
For instance, in January 2024, Zydus Lifesciences Limited secured approval for marketing and manufacturing Gabapentin tablets by the United States Food and Drug Administration. The product is primarily used for the management of Postherpetic Neuralgia, a condition known for causing lasting pain in the skin areas affected by shingles. The approval adds to the company’s 448 filed Abbreviated New Drug Applications (ANDAs) and 384 approvals. Such approvals allow market players to expand their customer base, supporting the market expansion.
Key Players Operating in Global Gabapentin Market are:
· Pfizer Inc.
· Zydus Cadila Healthcare Ltd.
· Glenmark Pharmaceuticals Ltd.
· Cipla USA, Inc.
· Novartis AG
· Sun Pharmaceutical Industries Ltd.
· Teva Pharmaceutical Industries Ltd.
· Ascend Laboratories, LLC
· Amneal Pharmaceuticals, Inc.
· Apotex Inc.
Markets and Data report answers the following questions:
· What is the current and future market size of the product/service in question globally or specific to different countries?
· How are the markets divided into different product/service segments and the market size and growth of each segment?
· What is the market potential of different product segments and their investment case?
· How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
· What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global gabapentin market, you may approach our team at info@marketsandata.com
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Voice of Customer
4.1. Market Awareness and Product Information
4.2. Brand Awareness and Loyalty
4.3. Factors Considered in Purchase Decision
4.3.1.Brand Name
4.3.2.Quality
4.3.3.Quantity
4.3.4.Price
4.3.5.Product Specification
4.3.6.Form Specification
4.3.7.Shelf Life
4.3.8.Availability of Product
4.4. Frequency of Purchase
4.5. Medium of Purchase
5. Global Gabapentin Market Outlook, 2017-2031F
5.1. Market Size & Forecast
5.1.1.By Value
5.1.2.By Volume
5.2. By Dosage Form
5.2.1.Oral Solution
5.2.2.Tablet
5.2.3.Capsule
5.3. By Application
5.3.1.Restless Legs Syndrome
5.3.2.Neuropathic Pain
5.3.3.Epilepsy
5.3.4.Others
5.4. By Route of Administration
5.4.1.Intravenous
5.4.2.Oral
5.4.3.Parenteral
5.5. By Mode of Purchase
5.5.1.Over-the-Counter
5.5.2.Prescription
5.5.3.Retail
5.6. By Distribution Channel
5.6.1.Retail Pharmacy
5.6.2.Hospital Pharmacy
5.6.3.Online Pharmacy
5.6.4.Others
5.7. By Region
5.7.1.North America
5.7.2.South America
5.7.3.Europe
5.7.4.Asia-Pacific
5.7.5.Middle East & Africa
5.8. By Company Market Share (%), 2023
6. Global Gabapentin Market Outlook, By Region, 2017-2031F
6.1. North America*
6.1.1.Market Size & Forecast
6.1.1.1. By Value
6.1.1.2. By Volume
6.1.2.By Dosage Form
6.1.2.1. Oral Solution
6.1.2.2. Tablet
6.1.2.3. Capsule
6.1.3.By Application
6.1.3.1. Restless Legs Syndrome
6.1.3.2. Neuropathic Pain
6.1.3.3. Epilepsy
6.1.3.4. Others
6.1.4.By Route of Administration
6.1.4.1. Intravenous
6.1.4.2. Oral
6.1.4.3. Parenteral
6.1.5.By Mode of Purchase
6.1.5.1. Over-the-Counter
6.1.5.2. Prescription
6.1.5.3. Retail
6.1.6.By Distribution Channel
6.1.6.1. Retail Pharmacy
6.1.6.2. Hospital Pharmacy
6.1.6.3. Online Pharmacy
6.1.6.4. Others
6.1.7.United States*
6.1.7.1. Market Size & Forecast
6.1.7.1.1. By Value
6.1.7.1.2. By Volume
6.1.7.2. By Dosage Form
6.1.7.2.1. Oral Solution
6.1.7.2.2. Tablet
6.1.7.2.3. Capsule
6.1.7.3. By Application
6.1.7.3.1. Restless Legs Syndrome
6.1.7.3.2. Neuropathic Pain
6.1.7.3.3. Epilepsy
6.1.7.3.4. Others
6.1.7.4. By Route of Administration
6.1.7.4.1. Intravenous
6.1.7.4.2. Oral
6.1.7.4.3. Parenteral
6.1.7.5. By Mode of Purchase
6.1.7.5.1. Over-the-Counter
6.1.7.5.2. Prescription
6.1.7.5.3. Retail
6.1.7.6. By Distribution Channel
6.1.7.6.1. Retail Pharmacy
6.1.7.6.2. Hospital Pharmacy
6.1.7.6.3. Online Pharmacy
6.1.7.6.4. Others
6.1.8.Canada
6.1.9.Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1.Germany
6.2.2.France
6.2.3.Italy
6.2.4.United Kingdom
6.2.5.Russia
6.2.6.Netherlands
6.2.7.Spain
6.2.8.Turkey
6.2.9.Poland
6.3. Asia-Pacific
6.3.1.India
6.3.2.China
6.3.3.Japan
6.3.4.Australia
6.3.5.Vietnam
6.3.6.South Korea
6.3.7.Indonesia
6.3.8.Philippines
6.4. South America
6.4.1.Brazil
6.4.2.Argentina
6.5. Middle East & Africa
6.5.1.Saudi Arabia
6.5.2.UAE
6.5.3.South Africa
7. Supply Side Analysis
7.1. Capacity, By Company
7.2. Production, By Company
7.3. Operating Efficiency, By Company
7.4. Key Plant Locations (Up to 25)
8. Market Mapping, 2023
8.1. By Dosage Form
8.2. By Application
8.3. By Route of Administration
8.4. By Mode of Purchase
8.5. By Distribution Channel
8.6. By Region
9. Macro Environment and Industry Structure
9.1. Supply Demand Analysis
9.2. Import Export Analysis
9.3. Value Chain Analysis
9.4. PESTEL Analysis
9.4.1.Political Factors
9.4.2.Economic System
9.4.3.Social Implications
9.4.4.Technological Advancements
9.4.5.Environmental Impacts
9.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
9.5. Porter’s Five Forces Analysis
9.5.1.Supplier Power
9.5.2.Buyer Power
9.5.3.Substitution Threat
9.5.4.Threat from New Entrant
9.5.5.Competitive Rivalry
10. Market Dynamics
10.1. Growth Drivers
10.2. Growth Inhibitors (Challenges and Restraints)
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Pfizer, Inc.
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. Zydus Cadila Healthcare Ltd.
14.3. Glenmark Pharmaceuticals Ltd.
14.4. Cipla USA, Inc.
14.5. Novartis AG
14.6. Sun Pharmaceutical Industries Ltd.
14.7. Teva Pharmaceutical Industries Ltd.
14.8. Ascend Laboratories, LLC
14.9. Amneal Pharmaceuticals, Inc.
14.10. Apotex Inc.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
List of Figures
Figure 1. Global Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 3. Global Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 4. Global Gabapentin Market Share (%), By Application, 2017-2031F
Figure 5. Global Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 6. Global Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 7. Global Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 8. Global Gabapentin Market Share (%), By Region, 2017-2031F
Figure 9. North America Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 11. North America Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 12. North America Gabapentin Market Share (%), By Application, 2017-2031F
Figure 13. North America Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 14. North America Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 15. North America Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 16. North America Gabapentin Market Share (%), By Country, 2017-2031F
Figure 17. United States Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 19. United States Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 20. United States Gabapentin Market Share (%), By Application, 2017-2031F
Figure 21. United States Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 22. United States Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 23. United States Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 24. Canada Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 26. Canada Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 27. Canada Gabapentin Market Share (%), By Application, 2017-2031F
Figure 28. Canada Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 29. Canada Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 30. Canada Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 31. Mexico Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 33. Mexico Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 34. Mexico Gabapentin Market Share (%), By Application, 2017-2031F
Figure 35. Mexico Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 36. Mexico Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 37. Mexico Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 38. Europe Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 40. Europe Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 41. Europe Gabapentin Market Share (%), By Application, 2017-2031F
Figure 42. Europe Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 43. Europe Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 44. Europe Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 45. Europe Gabapentin Market Share (%), By Country, 2017-2031F
Figure 46. Germany Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 48. Germany Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 49. Germany Gabapentin Market Share (%), By Application, 2017-2031F
Figure 50. Germany Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 51. Germany Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 52. Germany Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 53. France Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 55. France Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 56. France Gabapentin Market Share (%), By Application, 2017-2031F
Figure 57. France Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 58. France Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 59. France Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 60. Italy Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 62. Italy Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 63. Italy Gabapentin Market Share (%), By Application, 2017-2031F
Figure 64. Italy Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 65. Italy Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 66. Italy Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 67. United Kingdom Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 69. United Kingdom Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 70. United Kingdom Gabapentin Market Share (%), By Application, 2017-2031F
Figure 71. United Kingdom Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 72. United Kingdom Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 73. United Kingdom Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 74. Russia Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 76. Russia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 77. Russia Gabapentin Market Share (%), By Application, 2017-2031F
Figure 78. Russia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 79. Russia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 80. Russia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 81. Netherlands Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 83. Netherlands Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 84. Netherlands Gabapentin Market Share (%), By Application, 2017-2031F
Figure 85. Netherlands Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 86. Netherlands Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 87. Netherlands Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Spain Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 90. Spain Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 91. Spain Gabapentin Market Share (%), By Application, 2017-2031F
Figure 92. Spain Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Spain Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 94. Spain Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 95. Turkey Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 97. Turkey Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 98. Turkey Gabapentin Market Share (%), By Application, 2017-2031F
Figure 99. Turkey Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 100. Turkey Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 101. Turkey Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 102. Poland Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 104. Poland Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 105. Poland Gabapentin Market Share (%), By Application, 2017-2031F
Figure 106. Poland Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 107. Poland Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 108. Poland Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 109. South America Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 111. South America Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 112. South America Gabapentin Market Share (%), By Application, 2017-2031F
Figure 113. South America Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 114. South America Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 115. South America Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 116. South America Gabapentin Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 119. Brazil Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 120. Brazil Gabapentin Market Share (%), By Application, 2017-2031F
Figure 121. Brazil Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 122. Brazil Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 123. Brazil Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 124. Argentina Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 126. Argentina Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 127. Argentina Gabapentin Market Share (%), By Application, 2017-2031F
Figure 128. Argentina Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 129. Argentina Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 130. Argentina Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 131. Asia-Pacific Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 133. Asia-Pacific Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 134. Asia-Pacific Gabapentin Market Share (%), By Application, 2017-2031F
Figure 135. Asia-Pacific Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 136. Asia-Pacific Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 137. Asia- Pacific Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Asia-Pacific Gabapentin Market Share (%), By Country, 2017-2031F
Figure 139. India Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 141. India Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 142. India Gabapentin Market Share (%), By Application, 2017-2031F
Figure 143. India Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 144. India Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 145. India Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 146. China Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 148. China Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 149. China Gabapentin Market Share (%), By Application, 2017-2031F
Figure 150. China Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 151. China Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 152. China Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 153. Japan Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 155. Japan Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 156. Japan Gabapentin Market Share (%), By Application, 2017-2031F
Figure 157. Japan Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 158. Japan Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 159. Japan Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 160. Australia Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 162. Australia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 163. Australia Gabapentin Market Share (%), By Application, 2017-2031F
Figure 164. Australia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 165. Australia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 166. Australia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 167. Vietnam Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 169. Vietnam Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 170. Vietnam Gabapentin Market Share (%), By Application, 2017-2031F
Figure 171. Vietnam Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 172. Vietnam Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 173. Vietnam Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. South Korea Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 176. South Korea Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 177. South Korea Gabapentin Market Share (%), By Application, 2017-2031F
Figure 178. South Korea Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 179. South Korea Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 180. South Korea Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. Indonesia Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 183. Indonesia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 184. Indonesia Gabapentin Market Share (%), By Application, 2017-2031F
Figure 185. Indonesia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 186. Indonesia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 187. Indonesia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 188. Philippines Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 190. Philippines Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 191. Philippines Gabapentin Market Share (%), By Application, 2017-2031F
Figure 192. Philippines Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 193. Philippines Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 194. Philippines Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 195. Middle East & Africa Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 197. Middle East & Africa Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 198. Middle East & Africa Gabapentin Market Share (%), By Application, 2017-2031F
Figure 199. Middle East & Africa Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 200. Middle East & Africa Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 201. Middle East & Africa Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 202. Middle East & Africa Gabapentin Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 205. Saudi Arabia Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 206. Saudi Arabia Gabapentin Market Share (%), By Application, 2017-2031F
Figure 207. Saudi Arabia Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 208. Saudi Arabia Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 209. Saudi Arabia Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 210. UAE Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 212. UAE Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 213. UAE Gabapentin Market Share (%), By Application, 2017-2031F
Figure 214. UAE Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 215. UAE Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 216. UAE Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 217. South Africa Gabapentin Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Gabapentin Market, By Volume, In Kilotons, 2017-2031F
Figure 219. South Africa Gabapentin Market Share (%), By Dosage Form, 2017-2031F
Figure 220. South Africa Gabapentin Market Share (%), By Application, 2017-2031F
Figure 221. South Africa Gabapentin Market Share (%), By Route of Administration, 2017-2031F
Figure 222. South Africa Gabapentin Market Share (%), By Mode of Purchase, 2017-2031F
Figure 223. South Africa Gabapentin Market Share (%), By Distribution Channel, 2017-2031F
Figure 224. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Mode of Purchase Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
List of Tables
Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What is the market size and growth rate of global gabapentin market?
What regions are covered in the final report of global gabapentin market?
Who are the key players operating in global gabapentin market?
What are the major factors influencing the growth of global gabapentin market?
See Related Reports
Global Female Urination Devices Market Assessment, Opportunities and Forecast, 2017-2031F
Global female urination devices market is projected to witness a CAGR of 10.18% during the forecast period 2024-2031, growing from USD 2.72 billion in 2023 to USD 5.91 billion in 2031. ....Read More
Published on
May 2024
4,500
Global Packaged Coconut Water Market Assessment, Opportunities and Forecast, 2017-2031F
Global packaged coconut water market is projected to witness a CAGR of 11.24% during the forecast period 2024-2031, growing from USD 1538.6 million in 2023 to USD 3608.42 million in 2031. ....Read More
Published on
May 2024
4,500
Global Almond Market Assessment, Opportunities and Forecast, 2017-2031F
Global almond flour market is projected to witness a CAGR of 7.52% during the forecast period 2024-2031, growing from USD 1.51 billion in 2023 to USD 2.7 billion in 2031. ....Read More
Published on
May 2024
4,500
India Crop Insurance Market Assessment, Opportunities and Forecast, 2018-2032F
India crop insurance market is projected to witness a CAGR of 7.62% during the forecast period FY2025-FY2032, growing from USD 4.56 billion in FY2024 to USD 8.21 billion in FY2032. ....Read More
Published on
May 2024
3,300
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
